

IN THIS ISSUE

Correction: Reminder About Billing Preventive Codes..... 2
 Caring for Older Adults..... 2
 Talk to Patients About Avoiding Hospital Readmission..... 2
 Medical Policy Updates..... 2
 Pharmacy Updates..... 4
 Specialty Program Expansion..... 4
 United States Preventive Services Task Force 4

CVS/caremark is MVP's New Pharmacy Benefits Manager

Effective January 1, 2015, CVS/caremark will be MVP's Pharmacy Benefits Manager (PBM) for retail, mail, and specialty prescriptions.



- The CVS/caremark retail pharmacy network is expansive, with thousands of participating pharmacies nationwide.
- MVP members who have a mail order benefit will use the CVS Caremark Mail Service Pharmacy. Prescriptions that have refills will be transferred from the current mail order vendor. If you need to issue new prescriptions as a result of the change in mail order vendors, MVP will notify you in writing and include a list of affected members.
- MVP members who are on specialty medications will now use the CVS Caremark Specialty Pharmacy. Prescriptions that have refills will be transferred from the current specialty vendor. For your reference, the fax number for the CVS Caremark Specialty Pharmacy is **1-800-323-2445**.
- Prior authorizations that are active on and after January 1, 2015 will be transferred to the new adjudication system and you will not need to take any action. MVP will continue to administer the prior authorization function for all lines of business.
- MVP will continue to maintain four formularies in 2015:
 - MVP Commercial (Commercial, ASO, and Child Health Plus)
 - MVP Marketplace (New York and Vermont Exchanges)
 - MVP Medicare Part D
 - MVP Option and Option Family (Medicaid and Family Health Plus)

For additional information about the PBM change, please contact your MVP Professional Relations Representative. See page 4 for more Pharmacy updates.

Contacting MVP Provider Relations

MVP Corporate Headquarters	1-888-363-9485
Southern Tier	1-800-688-0379
Central New York	1-800-888-9635
Midstate	1-800-568-3668
Mid-Hudson	1-800-666-1762

Denise V. Gonick
President & CEO

Healthy Practices is a bi-monthly publication of the MVP Health Care Corporate Affairs Department.

We welcome your comments.
 Healthy Practices
 MVP Health Care, Inc.
 Professional Relations Dept.
 PO Box 2207
 Schenectady, NY 12301



PROFESSIONAL RELATIONS UPDATE

National Drug Code (NDC) Payment Policy Reminder

To be reimbursed for a medication that is administered in a physician office, outpatient setting, or hospital outpatient setting an NDC number and drug quantity must be included on all claims. An NDC number is not required for inpatient hospital claims or for drugs purchased through the 340B Program. MVP will verify each NDC for accuracy and any claim with an invalid NDC number will be rejected. For additional information and instructions on how to submit a valid NDC, please see MVP's NDC payment policy in Section 15 of the Provider Resource Manual.

Correction: Reminder About Billing Preventive Codes

The first paragraph in the **Reminder About Billing Preventive Codes** article in the September/October issue of *Healthy Practices* contained a broken link. To locate the complete list of preventive health services covered under the Affordable Care Act (ACA), please visit www.mvphealthcare.com and select *Reform* at the bottom of the homepage, then *Coverage*, and then *Preventive Health Care*; you will find the information under *Guide for Health Care Providers*. We apologize for any inconvenience.

CARING FOR OLDER ADULTS

Talk to Patients About Avoiding Hospital Readmission

In an effort to decrease readmission rates after a hospital stay, MVP is educating our Medicare Advantage Plan members on how to be prepared for a smooth transition from hospital to home.

Members who are better prepared before their discharge will have a lower chance of being admitted back into the hospital because of a problem.

Providing continuity and coordination of care for a patient as they transition from the hospital setting to outpatient is crucial to reducing hospital readmission rates. Health care providers can help by obtaining hospital discharge summaries in a timely manner and documenting any changes in medical/surgical history and medications. Patients often may have additional specialists involved in their care after a hospital stay. It is important for primary care providers (PCPs) and specialists to communicate relevant information to ensure a coordinated approach to the patients care. It is also very important for the patient to see their physician within 3 to 7 days of discharge.

We encourage physicians to speak with MVP Medicare Advantage Plan members about this important topic. Some helpful tips that members should follow include:

- Bring a complete list of medications to the hospital on the day of admission.
- Work with the discharge planning staff to make a hospital follow-up plan.
- Take an active role in discharge and treatment planning.

- Learn any important details about the condition and how they can take care of themselves.
- Schedule a follow-up appointment within seven days after leaving the hospital.
- Bring hospital discharge plan along with a list of medications to follow-up appointment(s).
- Carry important information at all times about the condition, medications, doctor, and pharmacy contact information.

To help members keep important information with them at all times, MVP has created a checklist to be used for planning. The checklist can be found by visiting www.mvphealthcare.com/provider and selecting *Provider Quality Improvement Manual*, then *Caring for Older Adults*, and then *Planning a Hospital Stay*.

MEDICAL POLICY UPDATES

The MVP Quality Improvement Committee (QIC) approved the policies summarized below during its October meeting. Some of the medical policies may reflect new technology, while others clarify existing benefits. *Healthy Practices* and/or *FastFax* will continue to inform your office about new and updated medical policies. MVP encourages your office to look at all of the revisions and updates on a regular basis in the Benefit Interpretation Manual (BIM) located on www.mvphealthcare.com. To access the BIM, log in to your MVP online account and select *Online Resources*, then *BIM* under *Policies*. The Current Updates page of the BIM lists all medical policy updates. If you have questions regarding the medical policies or wish to obtain a paper copy of a policy, contact your Professional Relations Representative.

Medical Policy Updates Effective December 1, 2014

Breast Surgery for Gynecomastia: there are no changes to the medical policy criteria and indications.

Bronchial Thermoplasty NEW: bronchial thermoplasty is considered investigational.

Burn Garments and Lymphedema Sleeves: there are no changes to the medical policy criteria and indications.

Cardiac Rehabilitation Phase II ARCHIVED: Cardiac Rehabilitation Phase II medical policy is now archived.

Cosmetic and Reconstructive Services: there are no changes to the medical policy criteria and indications.

Dental Care Services/Facility Services: there are no changes to the medical policy criteria and indications.

Durable Medical Equipment (DME): the policy language was updated to include the requirements for DME Vendors, DME repairs, and replacement wheelchairs.

Gene Expression Classifier (Afirma®) NEW: gene expression classifier (Afirma) for cytologically follicular lesion of undetermined significance is considered medically necessary.

Hospice Care: there are no changes to the medical policy criteria and indications. MVP Option and Option Child variations were clarified to be consistent with Medicaid coverage.

Hyperbaric Oxygen Therapy (HBO): there are no changes to the medical policy criteria and indications.

Knee Arthroscopy: there are no changes to the medical policy criteria and indications.

Repetitive Transcranial Magnetic Stimulation (rTMS) NEW: transcranial magnetic stimulation is a non-invasive procedure for the treatment of major depressive disorder. It may be indicated for patients who are resistant to other depression treatments. Transcranial magnetic stimulation is covered when the medical policy criteria are met.

Transcatheter Aortic Valve Replacement: there are no changes to the medical policy criteria and indications.

Policies reviewed and approved in 2013 for approval without changes in October 2014:

- Autism Spectrum Disorders NH
- Continuous Glucose Monitoring
- Endoscopy (Colonoscopy)
- Imaging Procedures
- Oxygen Therapy for the Treatment of Cluster Headaches

Medical Policy Updates Effective January 1, 2015

Investigational Procedures, Devices, Medical Treatments, and Tests NEW: this policy addresses procedures, devices, medical treatments, and tests not covered because they have not been proven to provide long-term safe and effective outcomes indicated by a preponderance of scientific evidence and, therefore, are considered investigational.

The following are services addressed in this policy:

- Athletic Pubalgia Surgery

- Immunotherapy for Recurrent Spontaneous Abortion
- Mechanical Devices to Treat Low Back Pain
- OnDose™ (Area under the Curve [AUC]-Targeted 5-Fluorouracil)
- OvaCheck® (Proteomic Pattern Analysis of Blood for the Early Detection of Ovarian Cancer)
- Platelet-Rich Plasma Injections
- Prolotherapy
- Thermal Intradiscal Procedures for Low Back Pain
- Tumor *InVitro* Chemosensitivity and Chemoresistance Assays
- Tumor Markers (OVA1™)
- Wireless Capsule for the Evaluation of Suspected Gastric Motility Disorders

The following policies are ARCHIVED.

Individual procedures are addressed in the Investigational Procedures, Devices, Medical Treatments, and Tests medical policy (above).

- Athletic Pubalgia Surgery
- Chemosensitivity and Chemoresistance Assays Tumor *InVitro*
- Immunotherapy for Recurrent Spontaneous Abortion
- Mechanical Devices to Treat Low Back Pain
- OnDose™ (Area under the Curve [AUC]-Targeted 5-Fluorouracil)
- OvaCheck® (Proteomic Pattern Analysis of Blood for the Early Detection of Ovarian Cancer) Platelet-Rich Plasma Injections
- Prolotherapy
- Thermal Intradiscal Procedures for Low Back Pain
- Tumor Markers (OVA1™)

Medical Policy Updates Effective February 1, 2015

The 2015 Ambulatory Surgery Procedure and In-Office Procedure lists were approved by the Quality Improvement Committee (QIC) in October and will be effective February 1, 2015. Coverage for the ambulatory procedures is limited to the ambulatory surgery, out-patient hospital, or in-office settings. Claims submitted with a place of service other than these settings will be denied unless prior authorization is obtained. Use of appropriate place of service setting does not override any existing prior authorization requirements.

Coverage for in-office procedures is limited to the in-office place of service. Claims submitted with a

place of service other than in-office will be denied unless prior authorization is obtained.

The 2015 Ambulatory Surgery Procedure and In-Office Procedure lists can be found at www.mvphealthcare.com by selecting *Providers*, and then *Reference*.

InterQual Criteria Medical Policies (NEW)

This policy lists procedures reviewed utilizing McKesson® InterQual criteria. The procedures addressed in this policy are:

- Capsule Endoscopy
- Laminectomy
- Pectus Excavatum
- Sclerotherapy for Varicose Veins
- Septoplasty
- Spinal Cord Stimulator
- Spinal Fusion
- Video EEG (no prior authorization required)

The following policies are **ARCHIVED**.

The individual procedures are addressed in the InterQual Criteria medical policy (above).

- Capsule Endoscopy
- Laminectomy
- Pectus Excavatum
- Sclerotherapy for Varicose Veins
- Septoplasty
- Spinal Cord Stimulator
- Spinal Fusion
- Video EEG

Miscellaneous Policies ARCHIVED as of January 1, 2015

- EEG Monitoring and Anesthesia Awareness
- Mifepristone
- Nesiritide Infusion for Heart Failure–Outpatient
- PEEK Instrumentation and Devices
- Pulmonary Rehabilitation (Respiratory PT)

PHARMACY UPDATES

Specialty Program Expansion

Effective January 1, 2015, MVP will expand the list of medications that are required to be filled through our specialty pharmacy vendor, the CVS Caremark Specialty Pharmacy. Drug classes that will be added to the list include, but are not limited to, infertility, select oncology, and liposomal storage diseases medications. MVP will notify you in writing if further action is required.

United States Preventive Services Task Force

Beginning January 1, 2015, medications (over-the-counter and prescription) that are required to be covered under the Affordable Care Act and which the United States Preventive Services Task Force (USPTF) rates “A” or “B” will adjudicate at the pharmacy point-of-service. These medications are covered in full, except tamoxifen and raloxifene for the primary prevention of breast cancer. More information on MVP’s coverage for these medications can be found in the *Preventive Services, Medication* policy.

Policy Updates Effective October 1, 2014

Agents for Hypertriglyceridemia

- Vascepa and generic Lovaza added
- Policy was previously named Lovaza

Cialis for BPH

- Myrbetriq added as a possible drug to fail in combination with an alpha-blocker

Otrexup NEW

- Policy criteria includes failure or intolerance to oral or generic injectable MTX

Pradaxa

- New DVT/PE indication added

Valchlor NEW

- Skin biopsy must identify Stage 1A or 2B mycosis fungoides-type cutaneous T-cell lymphoma
- Prescriber must be an oncologist or dermatologist
- Must have failed on select skin directed therapies

Policy Updates Effective November 1, 2014

RSV/Synagis

- Criteria updated to reflect changes to RSV guidelines

Policy Updates Effective January 1, 2015

Immunoglobulin Therapy

- For acute ITP, criteria updated to specify platelet count <30,000/uL
- Medicare variation updated to include coverage for SQ administration and for the use in MS
- J1556 added

Multiple Sclerosis Agents

- Drugs covered under the Rx benefit and medical benefit clarified. Drugs requiring prior authorization also clarified

Orphan Drugs and Biologicals

- Onfi removed from policy
- Cystaran, Procysbi, and Signifor added

Preventive Services, Medication

- Coverage for raloxifene and tamoxifen were added
- Coverage for vitamin D and bowel prep kits added
- Criteria for point-of-sale coverage added

Prostate Cancer

- Xtandi overview updated

Policies reviewed and approved without any changes to criteria

- Formulary Exception for Non-covered Drugs

Formulary Updates for Commercial, Option, and Marketplace Formularies

New drugs (recently FDA approved, prior authorization required, Tier 3, non-formulary for MVP Option/MVP Option Family)

Drug Name	Indication
Dalvance*	Acute bacterial skin infections
Entyvio*	Ulcerative colitis and Crohn's disease
Evzio	Emergency treatment of opioid overdose
Purixan	ALL
Sitavig	Herpes labialis
Sivextro	Acute bacterial skin infections
Sylvant*	Castleman's disease
Tanzeum	Type 2 diabetes
Vogelxo	Testosterone replacement
Xartemis XR	Pain
Zontivity	Reduction of thrombotic CV events
Zykadia†	Lung cancer

Drugs Added to Formulary (Tier 1)

donepezil 23mg estradiol patch paricalcitol^
valsartan^

Drugs Moved to Non-Formulary (Tier 3)

Aricept 23mg Climara Diovan

Drugs Removed from Prior Authorization

Brintellix Duavee Ecoza
Farxiga^D Fetzima ER Fycompa
Gazyva* Imbruvica Lupaneta Pak
Prothelial Stendra^{QL} Velphoro
Zorvolex

* Medical drug

† Must be obtained from Accredo Specialty Pharmacy

^ Tier 2 on Marketplace (Exchange) formulary

^D Diabetic copay

^{QL} Quantity limits apply



625 State Street
Schenectady, NY 12301-2207
mvphealthcare.com

PRSR STD
US Postage
PAID
MVP Health Care

get your

 **HEALTHY**
PRACTICESTM
by email

If you are not already getting *Healthy Practices* by email, sign up today! The email version is easy to share with your entire office.

Simply complete the form at www.mvphealthcare.com/providerpreferences to enroll in MVP e-communications.

